Results 91 to 100 of about 16,542 (247)
Background: Dupilumab is approved in Japan for the treatment of atopic dermatitis in patients aged 6 months to 18 years. However, long-term data are lacking in this patient population. Here we report the final analysis of a long-term open-label extension
Yoko Kataoka +12 more
doaj +1 more source
ABSTRACT Asthma affects 260–300 million people worldwide. About 20%–35% of patients use medicinal plants with their asthma medication, often without telling their clinicians. Disclosure rates are low; up to 42% of asthma outpatients use herbal products, with no records in their charts.
Emine Kocyigit +5 more
wiley +1 more source
Dupilumab side effect in a patient with atopic dermatitis: a case report study
Sakhar S Albader,1 Abdulmajeed A Alharbi,2 Rakan F Alenezi,1 Fahad M Alsaif31College of Medicine, King Saud University, Riyadh, Saudi Arabia; 2College of Medicine, Alqassim University, Qassim, Saudi Arabia; 3Division of Dermatology, College of Medicine ...
Alharbi AA +3 more
core
ABSTRACT Background Chronic rhinosinusitis (CRS) and nasal polyps (NP) are chronic inflammatory conditions with unsatisfactory treatment outcomes due to frequent recurrence of refractory disease. Identifying new therapeutic targets is essential. Methods We conducted a proteome‐wide Mendelian randomization (MR) analysis by integrating genome‐wide ...
En Zhou +4 more
wiley +1 more source
Dupilumab in children with eosinophilic esophagitis: a retrospective multicenter study
Background Eosinophilic esophagitis (EoE) is a chronic inflammatory disorder characterized by symptoms of esophageal dysfunction and eosinophil-predominant inflammation. Dupilumab is a human monoclonal antibody that targets both IL-4 and IL-13 signaling.
Mohammed Hasosah +11 more
doaj +1 more source
ABSTRACT Background Chronic rhinosinusitis with nasal polyps (CRSwNP) impacts patients' concentration, ability to work, and overall quality of life. Current treatment options include topical and oral medications, and surgery. Recent evidence supports the efficacy of biologics in improving symptoms and quality of life.
Baharudin Abdullah +19 more
wiley +1 more source
Dupilumab is a monoclonal antibody that has recently been introduced for the treatment of asthma. It has the potential to significantly alter the progression and severity of T2 -dependent diseases, including severe asthma.
Agnieszka Gawlewicz-Mroczka +4 more
doaj +1 more source
ABSTRACT Purpose The rising prevalence of obesity introduces challenges in surgical contexts, including endoscopic sinus surgery (ESS) for chronic rhinosinusitis with nasal polyps (CRSwNP). However, the impact of obesity on ESS outcomes remains underexplored. This study aims to evaluate the association between obesity and surgical complexity, operative
Hen Chaushu +6 more
wiley +1 more source
ABSTRACT Objective Chronic rhinosinusitis with nasal polyps (CRSwNP) is a persistent inflammatory condition often associated with other type‐2 diseases. Dupilumab, a monoclonal antibody targeting IL‐4Rα, has revolutionized the treatment of severe CRSwNP.
Pietro Orlando +17 more
wiley +1 more source
A Review of Dupilumab in the Treatment of Atopic Dermatitis in Infants and Children [PDF]
Mingyue Wang,1– 4 Xing-Hua Gao,1– 4 Li Zhang1 1Department of Dermatology, the First Hospital of China Medical University, Shenyang, 110001, People’s Republic of China; 2NHC Key Laboratory of Immunodermatology, China Medical University, Shenyang, People’s
Wang M, Gao XH, Zhang L
core

